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Abstract
Background: Consumption of baked egg by raw egg allergic children is associated with immune changes suggesting
development of tolerance. However, causation has not been tested using a double blind randomized controlled trial
(RCT). We aimed to compare clinical and immunological outcomes after baked egg (BE) consumption in young BE
tolerant egg allergic children.
Methods: In a double blind RCT, BE tolerant egg allergic children consumed 10 g BE (1.3 g protein) 2 to 3 times per
week for 6 months (n = 21 intervention group) or similar egg free baked goods (n = 22 control group) while maintaining
an otherwise egg free diet. The final assessment was a raw egg oral food challenge (OFC) 1 month after ceasing the
intervention product. Egg specific IgE and IgG4 were assessed at baseline and 7 months.
Results: After the intervention there was no difference in raw egg tolerance between groups, (23.5% (4/17) intervention
group and 33.3% (6/18) control group). This was independent of age and amount of BE consumed (aOR 0.50
CI 0.11–2.40 p = 0.39). Both groups demonstrated decreased egg specific serum IgE titres and decreased whole egg
specific IgE/IgG4 ratios.
Discussion: We conducted this trial because inclusion of baked egg protein in the diet of egg allergic children appears
to move children towards a more tolerant immune profile. Strengths of our study include design of the blinded
intervention, the consistent dosing protocol and the regular monitoring of symptoms and intake. However, the study
was limited by small sample size resulting in insufficient power to show statistically significant results.
Conclusion: Our study suggests that short term, regular consumption of BE by BE tolerant 1 to 5 year old children
with IgE mediated raw egg allergy may not induce, accelerate or slow development of tolerance to raw egg in this
selected population. Trials with larger sample sizes are required to further test this hypothesis.
Trial Registration: The trial was registered on 7th February 2012 with the Australian New Zealand Clinical Trials
Registry (ACTRN 12612000173897).
Keywords: Egg, Egg allergy, Baked egg, Food allergy, Oral tolerance, Randomised controlled trial
* Correspondence: merryn.netting@adelaide.edu.au
1Children’s Nutrition Research Centre, South Australian Health Medical
Research Institute, 72 King William Road, North Adelaide, South Australia
5006, Australia
2Discipline of Paediatrics, The University of Adelaide, Adelaide, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Netting et al. World Allergy Organization Journal  (2017) 10:22 
DOI 10.1186/s40413-017-0152-5
Background
Many egg allergic children tolerate baked egg (BE) before
less well-cooked forms of egg as heating causes structural
changes in some egg epitopes and there is a matrix effect
when egg is baked with wheat that may also be important
[1–4]. Inclusion of BE in the diet of egg allergic children,
when tolerated, has become accepted clinical practice [5–8]
and it is reported that individuals consuming BE tolerate
lightly cooked egg earlier than those not consuming BE
[9, 10]. Regular consumption of BE is associated with in-
creases in specific IgG4, and decreases in specific IgE
[1, 11], immunological changes similar to those observed
during specific oral tolerance induction (SOTI) [12]. From
this it was hypothesised consumption of BE could promote
tolerance to uncooked egg protein [13].
It remains unclear, in children with raw egg allergy toler-
ant to BE if ingestion of BE accelerates tolerance acquisition
to raw egg as randomised controlled clinical trials (RCT)
have not been undertaken. It is also not clear from observa-
tional studies whether BE tolerant children who gain raw
egg tolerance earlier than those not tolerant to BE were
moving towards natural resolution of their egg allergy, or if
this was due to changes with time or other unidentified
confounders [1, 11].
Our study’s primary aim was to determine whether raw
egg allergy is better resolved by regular consumption of BE
(intervention group) compared with an egg free diet (con-
trol group). We also examined the effect of regular BE




Six month old to five year old children with IgE mediated
egg allergy following egg free diets were recruited from the
Women’s and Children’s Hospital Allergy Clinic. Following
recruitment all children had egg allergen SPT (see Appen-
dix 1). Egg allergy was defined as children with a convincing
clinical reaction to egg within the past 12 months and evi-
dence of current sensitisation on the basis of positive SPT
to egg white or evidence of current sensitisation consistent
with a >95% likelihood of clinical reactivity (SPT to egg
white ≥ 5 mm if aged under 2yo, or ≥ 8 mm in children aged
2 to 5yo) [14, 15]. To assess BE tolerance, all children had
an open, medically supervised BE oral food challenge (OFC)
(10 g of egg in a muffin) [16]. BE tolerant children with EW
SPT <5 mm (6 months to 2yo) or <8 mm (2 to 5yo), who
reported no clinical reactions to raw egg in the previous
12 months had an open pasteurised raw egg OFC [17] to
confirm they still had a raw egg allergy.
The study was conducted using a double-blind, rando-
mised, placebo controlled trial design. Baseline charac-
teristics including demographics, allergy history and
anthropometrics (weight and length or height) were
gathered. For those children with eczema the clinical se-
verity was scored using the SCORAD assessment [18].
A peripheral blood sample was collected to measure
baseline whole egg (WE), egg white (EW), ovalbumin
(OVA) and ovomucoid (OVM) specific IgE (sIgE), WE
specific IgG4 (sIgG4) and functional cell response profiles.
Written informed consent was obtained before trial par-
ticipation. Approval was granted by the local institutional
review board (Human Research Ethics Committee;
REC2400/9/14) of the Women’s and Children’s Health
Network Adelaide, Australia, and the trial registered with
the Australian New Zealand Clinical Trials Registry
(ACTRN 12612000173897).
Randomisation and concealment allocation
Each child was randomly assigned to the intervention group
or the control group using a computerised randomisation
schedule stratified by age (6 months to 2.5 years and
2.6 years to 5 years). A research assistant (with no involve-
ment in the outcome assessments) was responsible for
baking and coding the dietary products for the trial.
Dietary intervention
The study compared the effects of inclusion of baked egg
containing (intervention group) or egg free (control group)
products in the diet of raw egg allergic children for 6
months after randomisation. Both groups maintained an
otherwise egg free diet with study muffins, biscuits (cook-
ies) or cake offered to the child for consumption 2 to 3
times per week for 6 months. The intervention group con-
sumed 10 g BE (1.3 g egg protein) per serve. The control
group consumed egg free products tested for similarity in
terms of appearance, taste, and texture. Intervention prod-
ucts were offered 2 to 3 times a week (consistent with the
Australian Dietary Guidelines for inclusion of ‘discretionary
foods’ in a child’s diet [19]).
To assess compliance with the intervention, care givers
maintained an intake and symptom diary, participants were
reviewed 1 month after randomisation and telephoned
monthly for the study duration.
After 6 months the intervention was stopped and
children continued an egg free diet for an additional
month, to differentiate between desensitisation and
development of sustained unresponsiveness to egg [20].
Adverse events were defined as flares in eczema, urticaria,
angioedema or vomiting associated with intake of the inter-
vention product or hospitalisation for any reason greater
than 24 h. Serious adverse events (defined as any death,
admission to intensive care, or anaphylactic reaction) were
reported to the institutional review board.
Outcome assessments
The primary outcome was raw egg allergy 1 month after
the intervention ended, assessed by an open medically
Netting et al. World Allergy Organization Journal  (2017) 10:22 Page 2 of 9
supervised, graded pasteurised raw whole egg OFC
[17, 21]. A positive reaction to an OFC was defined by
symptoms within 2 hours of the OFC according to the
PRACTALL Guidelines [22, 23]. SPT to EW was performed
prior to the OFC.
Analysis of immune outcomes
To assess sensitisation egg allergen (WE, EW, OVA and
OVM) sIgE levels were measured. WE sIgG4 was used
as a marker of tolerance. The sIgE and sIgG4 were
analysed at the end of the trial (maintaining blinding of
the sample ID). T cell surface markers and Th1/Th2
cytokines were also analysed (see Appendix 2).
Statistical analysis
A sample size estimate was calculated based on the known
natural history of egg allergy expecting after 6 months of
management with an egg free diet 90% of children would
still be egg allergic [2]. We hypothesized regular exposure
to BE would result in 30% absolute reduction (ie from 90 to
60%) of egg allergy. To detect such a difference with 90%
power and p = 0.05, we estimated we would need 49
children per group (total n = 98) and aimed to recruit 55
children to each group to allow for withdrawals from the
study. However, after screening 83 children for BE tolerance
over 20 months, and enrolling 43 participants, screening
for the study ceased due to resource constraints.
Analyses were performed according to the randomized
group using STATA 13.1 (StataCorp LP) or the InStat pro-
gram v 6.05 (Graph Pad software, USA). Statistical signifi-
cance was assessed at the 0.05 level. The proportion of
children tolerant to egg at the study’s end was compared
between groups. Secondary comparisons between groups
included changes in sIgE and sIgG4 results and other im-
mune outcomes. For sIgE and sIgG4 results, standard linear
regression was performed including the baseline level as a
covariate to ensure estimated differences between groups
were not biased due to differences in baseline wheal size
and/or regression to the mean effects. For ‘adjusted’
analyses, age stratum was also included. In all cases, sensi-
tivity analyses (removal of outlying/influential observations)
were undertaken, and did not affect the conclusions.
Change between groups was assessed using the Wilcoxon
Rank-Sum Test.
For other immune outcomes a non-parametric ap-
proach was used for analysis because of highly skewed
distributions of all variables and small sample sizes.
Results
Randomization occurred from 22 May 2012 to 20 January
2014. The final follow up appointment was completed on 8
October 2014. While we intended to screen from 6 months
of age many babies could not tolerate the texture of baked
egg, so screening challenges were scheduled from 1 year of
age. The outcomes of the screening BE OFCs are in Appen-
dix 3.
We randomised 43 children (n = 21 intervention
group; n = 22 control group), aged 1.0 to 5.3 years. Both
groups had similar family and clinical backgrounds
(Table 1). Four parents withdrew consent and 38 chil-
dren (19 from each group) attended primary outcome
assessments (Fig. 1).
Clinical outcomes
Tolerance to raw egg after the intervention
Thirty-five children had raw egg OFCs (n = 17 interven-
tion group; n = 18 control group), (Fig. 1). 23% (4/17)
children from the intervention group and 33% (6/18)
control group passed the raw egg OFC and were there-
fore egg tolerant. There was no difference between
groups in likelihood of tolerating raw egg (Odds Ratio
[OR], 0.62; 95% CI, 0.14–2.73; p = 0.52), even after age
adjustment (OR 0.50; CI, 0.11–2.40; p = 0.39).
Per protocol analysis comparing children consuming 2 to
3 serves per week of study product 42% (4/19, intervention
group), 68% (13/19, control group) demonstrated no differ-
ence between groups in the proportion passing the raw egg
OFC (OR, 1.2; CI, 0.185–7.77; p = 0.85). Adjusted analysis
was not performed because of small numbers.
There were three protocol deviations due to clinical
decisions not to proceed with the end of study raw egg
Table 1 Demographic and clinical characteristics of children at
study entry




Maternal age (years)a 35.67 (3.7) 34.14 (3.7)
Maternal ethnicity Caucasianb 16 (76%) 19 (86%)
Age at screening (years)c 2.00 (1.21–3.25) 2.13 (1.29–3.12)
Male sexb 14 (67%) 16 (73%)
First degree relative with atopyb 18 (86%) 18 (82%)
Birth weight (grams)a 3509 (538) 3592 (470)
Gestational age at birth (weeks)a 38.9 (1.0) 38.7 (1.0)
Ever breastfed?b 21 (100%) 20 (91%)
Breastfed at screening?b 2 (10%) 2 (9%)
Age at diagnosis of egg allergy
(months)a
9.5 (4.3) 7.7 (3.4)
History of anaphylaxis to egg?b 3 (14%) 5 (23%)
Other IgE mediated food allergiesb 15 (71%) 18 (82%)
Eczemab 15 (71%) 19 (86%)
Eczema severity (Objective
SCORAD score)c
1.80 (0.00–12.33) 3.90 (0.00–9.0)
Asthma (Doctor diagnosed)b 2 (9.5%) 6 (27%)
Values are presented as follows: amean (SD), bnumber (percentages) or
cmedian (IQRs)
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OFC. Two children who had refused to eat the study prod-
uct had high EW SPT values (intervention group n = 1,
12.5 mm wheal; control group n = 1, 24.5 mm wheal) and
instead of raw egg OFCs had BE OFCs (passed). It is not
known if these children would have passed the raw egg
OFC if given. One child (intervention group) did not have a
raw egg OFC due to an accidental reaction to semi-cooked
egg the week prior to the appointment, and would have
reacted to the raw egg OFC. Inclusion of this child in the
analysis would not change the final outcome of the trial.
Compliance with the intervention
Participants were offered 2324 serves of intervention prod-
uct during the study. Intervention group children were of-
fered fewer (1065) serves, consuming a median of 1.6 (IQR
0.7–2.6) serves per week, compared with the control group
offered 1259 serves, consuming 2.3 (IQR 1.4–2.7) serves per
week. The differences between groups were not significant.
Compliance with the egg free diet
One child (intervention group) had several accidental
exposures to egg during the course of the study. This
child did not have the end of study raw egg OFC due
to a recent reaction to semi-cooked egg. No other
accidental exposures to egg were reported by partici-
pants in the study.
Adverse events
Nine children in the intervention group and eight children
in the control group reported adverse events (Table 2). One
child (control, egg free group) was diagnosed with Eosino-
philic Oesophagitis during the study. Three serious adverse
events were reported (anaphylaxis treated with adrenaline
Fig. 1 Study participant flow diagram. OFC =Oral food challenge. A Suboptimal baked egg oral food challenge was defined as failure to consume an
adequate amount of the challenge food
Table 2 Adverse events
Intervention group Control group
Related to ingestion of
the study product
Related to ingestion of
the study product
No Yes Unclear No Yes Unclear
Urticaria 2 1
Eczema flares 2 1 5





avomiting in both cases was associated with reintroduction of study product
after gastroenteritis
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during the raw egg OFC [n = 2 intervention group; n = 1
control group]).
Immunological outcomes
Egg allergen specific IgE results
Egg allergen sIgE levels did not differ between interven-
tion groups from baseline to end of the intervention when
compared using linear regression analysis for effect of
group allocation on outcome, adjusted for age stratum.
For both groups we observed significant reductions with
time in median specific IgE levels (kUA/L) to WE, (BE
group 3.33 (0.75–11.62) to 2.20 (0.47–8.01), p = 0.04;
control group 1.71 (0.19–6.94) to 1.26 (0.19–6.01), p= 0.01),
EW (BE group 3.72 (0.82–11.62) to 1.61 (0.42–8.17),
p = 0.04; control group 1.95 (0.28–11.60) to 1.66 (0.14–
8.55), p < 0.01) and OVA sIgE (BE group 2.57 (0.64–7.40) to
1.23 (0.29–5.23), p = 0.01; control group 1.48 (0.33–5.29) to
0.75 (0.15–4.05), p < 0.01) (Fig. 2).
Whole egg serum specific IgG4 and IgE to IgG4 ratio
results
There was no significant difference in WE sIgG4 levels
within the intervention and control groups or between
the groups from baseline to end of the intervention. [BE
group (0.16 (0.02-1.5) to 0.64 (0.10-1.88), p = 0.3);
control group (0.16 (0.01–0.79) to 0.27 (0.09–0.99), p= 0.3)]
(Fig. 3).
No difference in median WE specific IgE/IgG4 ratio was
observed between groups during the intervention. However,
a significant decrease in the median WE IgE/IgG4 ratio (in-
dicative of evolving tolerance to egg) was observed with
time in both BE intervention (15.63 (3.51–35.00) to 2.91
(0.88–9.21), p = 0.02) and control groups (17.50 (3.86–
50.18) to 8.28 (0.74–14.13), p = 0.04) (Fig. 4).
Cellular immune analysis
We assessed Th1/Th2 cytokines and T cell phenotypes,
with no significant difference observed between groups
(data not shown).
Discussion
This double blind, placebo controlled RCT compares the
effect of consumption of BE (with avoidance of all other
forms of egg) in 1 to 5 year old BE tolerant, raw egg allergic
children on the development of tolerance to raw egg. In
our study group, development of tolerance to raw egg was
independent of consumption of BE. We conducted this trial
because inclusion of baked egg protein in the diet of egg al-
lergic children appears to move children towards a more
tolerant immune profile [13]. In addition inclusion of baked
proteins in the diet, when tolerated, improves quality of life.
Strengths of our study include design of the blinded
intervention, the consistent dosing protocol and the regular
monitoring of symptoms and intake. Randomized groups
were of similar age, allergy background and egg allergy
phenotype, and the timing of assessments for clinical and
immunological outcomes add additional strength to our
results. We acknowledge that the small sample size is a
major limitation because of the resulting insufficient power
to show statistically significant results. Over 200 families of
egg allergic children were approached regarding the trial,
and of the children screened for the trial, only half tolerated
BE, which was less than expected [1, 24]. There are several
potential explanations for the lack of difference between
the two trial arms:
 Small sample size, and thus the lack of difference may
be due to chance.Whilst our study was underpowered,
Fig. 2 Changes in egg specific IgE from baseline to end of intervention. Changes in egg allergen specific IgE levels from the beginning to end of
the intervention. Box and bars indicate the median and IQR
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we did not see trends suggesting any effects on either
clinical or immunological outcomes.
 The time period of the intervention may have been too
short. However, decreased SPT wheal sizes and egg
sIgE, and increased sIgG4 have been reported after 3 to
6 months exposure to BE [1, 11], leading to conjecture
that inclusion of BE, when tolerated, in the diets of egg
allergic children may modulate the immune system
[8, 13, 25, 26]. In our group of BE tolerant children,
there was no difference between groups in reduction in
egg allergen sIgE levels or increase inWE sIgG4 levels.
Our results are consistent with Tey et al. [27], who
reported no difference in the rate of decline in EW
SPT wheal size in 3 to 6 year old egg allergic children
consuming BE compared with an egg free diet
indicating that this change may be independent of
consumption of BE.
 The dose of BE may have been too low, or too
infrequent. To comply with Australian healthy eating
guidelines related to consumption of ‘discretionary
foods’ [19] we asked the children to consume the study
foods 2 or 3 times per week. This dose rate is consistent
with the maintenance phase of several egg SOTI
studies [28–30], but less frequent than Lemon-Mule et
al. [1] who dosed 1 to 3 times daily. In our study, three
children (6%) (n= 2 intervention group; n = 1 control
group), refused to consume intervention products pos-
sibly due to finicky eating, or related to the texture of
the study products. Poor compliance has also been re-
ported in other immunotherapy trials [31, 32], includ-
ing other BE trials [33], and also was recently reported
in the EAT study[34]. It is possible that some children
in our study may have lost tolerance to BE, reflected by
refusal to consume the study product. Development of
symptoms when consuming BE and subsequent refusal
to consume BE has been reported in children passing
BE OFCs [16]. Participants in our study kept an intake
and symptom diary (including signs of abdominal pain
and other non IgE mediated allergies). Abdominal
pain was only reported by one child in the BE group.
Adjusting for total consumption of BE in our final
analysis made no difference to the outcome.
 As was common practise when we designed this trial,
to test for sustained unresponsiveness, participants in
the trial had a 4-week break from BE prior to the end
of study PE challenge. This may have affected the
outcome of the trial compared with an OFC at the end
of the 6 month period of BE ingestion.
 Ingestion of BE does not alter the resolution of raw egg
allergy (i.e. the study finding of no effect is true). A
population based study of 2 year-old BE tolerant, egg
allergic children demonstrated frequent ingestion of BE
was associated with earlier resolution of egg allergy
[24]. Once BE intolerant children developed BE toler-
ance they were as likely to gain tolerance to regular egg
as children initially tolerant to BE [24]. This may reflect
a phenotype outgrowing their egg allergy more quickly
than those self-limiting their BE intake.
There are no reports of controlled studies considering
the effects of BE in the diets of older cohorts of egg
allergic children, and such studies are warranted as BE
may modulate the immune system in children with more
resistant phenotypes of egg allergy.
Conclusion
Our study suggests that short term, regular consumption of
BE by BE tolerant 1 to 5 year old children with IgE medi-
ated raw egg allergy may not induce, accelerate or slow
development of tolerance to raw egg in this selected
Fig. 4 Changes in whole egg specific IgE/IgG4 ratios from baseline
to end of intervention. Changes in whole egg specific IgE / IgG4
ratio from the beginning to end of the intervention. Median and
IQR indicated
Fig. 3 Changes in whole egg specific/IgG4 from baseline to end of
intervention. Changes in whole egg specific IgG4 from the beginning
to end of the intervention. Median and IQR indicated
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population. Trials with larger sample sizes are required to
further test this hypothesis.
Appendix 1: Methods
Skin prick testing
To assess sensitisation to egg allergens, the children were
skin prick tested to the common egg allergens, according
to standard methods [35]. The allergen extracts used were
egg white (Alyostal # 143, AUST R32582)(1:20 w/v), egg
yolk (Alyostal # 144, AUST R32582)(1:20 w/v), (The Link
Group/Stallergenes, Suburb, NSW), whole egg (ALK-
Abello USA) (1:100 w/v), ovalbumin (ALK–Abello Spain;
Allergen # 6.22)(1:20 w/v), and ovomucoid (ALK-Abello
Spain; Allergen # 6.23)(1:20 w/v), (Australasian Medical
and Scientific Ltd, Suburb, NSW). The negative control
used was 50% (w/v) glycerin/saline (Holister-Steir Labora-
tories, Spokane, WA, USA) and the positive control was
histamine phosphate (10 mg/ml, B 0911308) supplied by
The Department of Pharmacy, Royal Adelaide Hospital,
Adelaide, South Australia. A positive skin prick test to an
allergen was defined as a mean of two perpendicular
wheal diameters of 3 mm or greater in size than the mean
wheal of the negative control site at 15 min.
Measurement of antigen specific ige
Serum whole egg, egg white, ovalbumin and ovomu-
coid specific IgE and whole egg specific IgG4 concen-
trations in plasma were measured using the Phadia
CAP system by the Department of Immunopathology,
SA Pathology at the Women’s and Children’s
Hospital, using NATA accredited methodologies as
per SA Pathology protocols.
Appendix 2 Immunological methodology
Immune memory development was assessed by
CD45RA/CD45RO, and staining with CCR7 allowed
assessment of changes in effector and central memory
to be detected. To further assess immune activation
peripheral blood mononuclear cells (PBMCs) sampled
at baseline and the end of the intervention were incu-
bated with OVA or OVM and assessed for T cell
CD69 expression and cytokine excretion from the
PBMCs was also measured to assess changes in the
Th1/Th2 balance.
Peripheral blood samples were collected at the
screening and 7 month visits and processed immedi-
ately. Plasma was collected after centrifugation and
stored at −80C for determination of serum specific
IgE/IgG4 levels. Peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque (Alexis-
Shield, Oslo, Norway) gradient centrifugation and iso-
lated cells cryopreserved in 80% heat inactivated
FCS (Sigma-Aldrich, Sydney, Australia) and 20%
dimethyl sulfoxide (Ajax Finechem, Taren Point,
NSW, Australia). Cell number and viability was
assessed by Trypan Blue.
For the cell culture experiments, PBMCs (106 cells/ml)
were cultured with 100 μg/ml egg allergens OVA and
OVM (Sigma-Aldrich, Sydney, Australia) for 5 days at
37 °C and 5% CO2. Cells cultured with AIM-V medium
(Invitrogen, Life Technologies Sydney, Australia) alone
served as a no-antigen control, and phytohemagglutinin-
L (PHA-L) (1 ug/ml) (Roche Diagnostics, Australia or
Remel, KS, USA) was used as the positive control. At
day 3 (for PHA-L stimulated cells) and day 5 (for OVA,
OVM and no antigen control) all available cells were
harvested and analysed. Cells were centrifuged at 300xg
for 5 min and the resulting supernatants collected and
stored at −80 °C for cytokine analysis. The cell pellet
was then equally divided into FACS tubes for labelling
with mouse anti human conjugated monoclonal anti-
bodies specific for cell surface antigens. Combinations of
fluorophores PE, PE-Cy7, FITC, APC, APC-Cy7 or
PerCP were used to assess the phenotype of the cells.
All antibodies (except CCR7) were purchased from BD
Biosciences (San Jose, CA, USA). CCR7 was purchased
from (Miltenyi Biotec, Auburn, SD, USA). Cells were
acquired on a BD Biosciences FACS Canto flow
cytometer (Becton Dickinson, CA, USA). Isotype
controls were used to set up the instrument and the
positive gating, and these settings were maintained
throughout. After selecting a lymphocyte gate based
on forward and side-scatter characteristics, events
within the lymphocyte gate were analysed using BD
FacsDiva™ software version 6.1.3 (BD Biosciences, San
Jose, CA, USA).
For the immunophenotyping cells were stained at
baseline for CD4, CD8, CD14, CD19 and HLA DR. To
assess activation, cells were stained with CD69 at base-
line and after incubation with OVA and OVM and to
assess memory markers cells were stained with
CD45RO, CCR7, CD27 and CD28.
The cytokine concentration in supernatants collected
on days 3 and 5 after incubation with OVA or OVM was
assessed using a BD Cytometric Bead Array Human
Inflammatory Cytokine Kit (IL-8, Il-1, IL-6, TNF, IL-12
and IL-10) and individual cytokines IL-4, IL-5 and IFNγ
were measured using the BD Biosciences enhanced
sensitivity flex sets for Human IL-4, Human IL-5 and
Human IFNγ and a BD Cytometric Bead Array (CBA)
Human enhanced Sensitivity Master Buffer Kit (BD
Biosciences, San Jose, CA, USA). (Minimum levels of de-
tection: IL-8, 2.6 pg/ml; IL-1, 7.2 pg/ml; IL-6 2.5 pg/ml;
IL-10 3.3 pg/ml; TNF, 3.7 pg/ml; IL-12, 1.9 pg/ml).
Beads were acquired on a BD Biosciences FACS Canto
flow cytometer (Becton Dickinson, San Jose, CA, USA)
and analysed using BD FacsDivaTM software version
6.1.3 (BD Biosciences, San Jose, CA, USA).
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Appendix 3: Results of screening baked egg oral
food challenges
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Comments regarding Table 2: a51.8% (43/83) were BE tolerant, egg allergic (8/48
BE tolerant children had raw egg OFC, 6/8 tolerated raw egg and were excluded
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